PureTech Health plc appointed Robert Lyne as CEO and board member. Near-term priorities include funding for Celea Therapeutics post positive FDA meeting. Operational costs to decrease post financing. Plans for streamlined structure and disciplined investment approach. Seeking financing for Gallop Oncology. Stock closed at $16.73 on Nasdaq.

Read more at Nasdaq.: PureTech Health Appoints Robert Lyne As CEO; Focuses On Financing For Celea, Gallop Oncology